Evidence map›Paper›PMID 38798207›Full record

ReviewCurrent diabetes reviews2025

Assessment for Diabetic Neuropathy: Treatment and Neurobiological Perspective.

Bhanupriya Bhrigu, Shikha Sharma, Nitin Kumar, Bimal Krishna Banik

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Diabetic neuropathy: cutting-edge research and future directions.Signal transduction and targeted therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bhanupriya BhriguDepartment of Pharmaceutical Science, Lords University, Alwar, 301028, Rajasthan, India.ORCID 0009-0004-8126-0433
Shikha SharmaDepartment of Pharmaceutical Science, Lords University, Alwar, 301028, Rajasthan, India.ORCID 0000-0002-9717-7819
Nitin KumarDepartment of Pharmaceutical Science, Lords University, Alwar, 301028, Rajasthan, India.ORCID 0009-0008-9517-8739
Bimal Krishna BanikDepartment of Mathematics and Natural Sciences, College of Sciences and Human Studies, Prince Mohammad Bin Fahd University, Al Khobar, Kingdom of Saudi Arabia.ORCID 0000-0002-7873-9062

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic neuropathy, also known as diabetic peripheral sensorimotor neuropathy (DPN), is a consequential complexity of diabetes, alongside diabetic nephropathy, diabetic cardiomyopathy, and diabetic retinopathy. It is characterized by signs and symptoms of peripheral nerve damage in diabetes patients after ruling out other causes. Approximately 20% of people with diabetes are affected by this painful and severe condition. The development of diabetic neuropathy is influenced by factors such as impaired blood flow to the peripheral nerves and metabolic issues, including increased polyol pathway activation, myo-inositol loss, and nonenzymatic glycation. The present review article provides a brief overview of the pathological changes in diabetic neuropathy and the mechanisms and types of DPN. Various diagnostic tests and biomarkers are available to assess nerve damage and its severity. Pharmacotherapy for neuropathic pain in diabetic neuropathy is complex. This review will explore current treatment options and potential future developments to improve the quality of life for patients suffering from diabetic neuropathy.

Indexed as

Diabetic NeuropathiesBiomarkersHumansNeuralgiaQuality of LifeBiomarkersdiabetes mellitus.Diabetic neuropathymechanism of diabetic neuropathy developmentpharmacotherapy polyol pathwayretinopathysepsis complications

Identifiers

PMID38798207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.